Organ-on-a-Chip Resources

Why the FDA animal testing phase-out for monoclonal antibodies?

In a groundbreaking press release on April 10th, 2025, the FDA announced its decision to phase out animal testing requirements for monoclonal antibodies, followed by other drugs – signaling a clear shift towards the use of more relevant human approaches for preclinical safety and toxicity testing.

Microphysiological systems for mAbs development: how do they address animal limitations?

Part two of our blog series exploring the FDA’s announcement to phase out the animal testing requirement for monoclonal antibodies (mAbs), and other drugs, in favor of human-relevant new approach methodologies (NAMs).

How OOC can improve in vitro to in vivo translatability of preclinical data

Organ-on-a-chip: a modernized toolbox for drug discovery challenges

Transforming drug discovery with a modernised toolbox. OOC is transforming accuracy, reducing failures, and accelerating new therapies.

PhysioMimix® bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Discover the PhysioMimix® Bioavailability assay kit: Human 18, the only in vitro tool for profiling human bioavailability. This Organ-on-a-chip solution bridges the gap between in vitro and in vivo studies, enhancing preclinical ADME testing for CROs, pharma, and biotech. Explore how it streamlines lead optimization and improves drug development accuracy.

PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights

Confidently predict DILI with PhysioMimix DILI assay kit: Human 24-accurate, human-relevant mechanistic hepatotoxicity insights to enhance drug safety in development

Advancing oligonucleotide therapies with liver-on-a-chip models

Webinar Series 8 Episode 1

Discover how human-relevant models improve the understanding of drug delivery, efficacy, and safety of oligonucleotide therapies.

A liver microphysiological system to study the delivery and efficacy of oligonucleotide-based therapeutics

We introduce the PhysioMimix Liver MPS to study the delivery of oligonucleotides into the liver and their uptake by PHHs. The Liver MPS produces functional and stable PHH microtissues, enabling the study of gene knockdown and dosing strategies over 14 days.

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

Multimodal imaging of a liver-on-a-chip model using labelled and label-free optical microscopy techniques

This recent multimodal imaging publication by Majer et al. (2024) from GSK explores the groundbreaking potential of 3D imaging of Liver-on-a-chip tissue to evaluate one of the biggest challenges in therapeutic ASOs: delivering oligonucleotides in sufficient concentration to the target tissue and cells of interest.

Validating a human dual-organ MPS for better drug (ADME) studies

In this video from Technology Networks’ Science Spotlight, Dr. Yassen Abbas, Lead scientist at CN Bio, discusses his research on ADME and how microphysiological system (MPS), also known as Organ-on-a-chip (OOC) technology can be used to evaluate the body’s effect on drugs.

The Rise of Oligonucleotide Therapeutics: Overcoming ADMET Development Challenges with Human-Centric Approaches

When developing oligonucleotide therapeutics, human-centric approaches are crucial for overcoming ADMET challenges and unlocking their full potential.

Find out through case studies how and why Organ-on-a-chip offers a path forward for the development of oligonucleotides targeting liver diseases by providing clearer insights into human-specific responses where in vivo models are less/unsuited.